Abstract
In a Blood Spotlight, Stephens reviews the evidence supporting the administration of venetoclax and obinotuzumab for frontline treatment of chronic lymphocytic leukemia and places the combination in the context of other accepted up-front therapies.
Publisher
American Society of Hematology
Subject
Cell Biology,Hematology,Immunology,Biochemistry
Cited by
5 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献